The COVID-19 keeps rampant in the human society from 2018 till now. Under the spread of the contagion, coronavirus vaccines are crucial factors to control the outbreak of the disease. Meanwhile, whether investing in companies developing COVID-19 vaccines becomes the research focus among investors. In this paper, fundamental stock analysis is applied as a method to investigate which companies in COVID-19 vaccine industry has the most promising prospect and will perform better in the future. The analysis of stocks is based on four aspects: valuation, profitability, growth, and payout, where the corresponding indicators are price to earnings ratio, earning per share growth, return on asset and equity, and dividend yield. After comparison of indicators of the main companies in the U.S. vaccine industry, suitable underlying assets are suggested to different types of investors. However, there are some limitations for using financial ratios to predict the future stock price in consideration of social fluctuations and fiscal policies. Therefore, further research ought to focus on how to combine fundamental stock analysis with technical method and social factors. These results shed light on guiding further exploration of stock selection based on fundamental analysis.